Clara D. Bloomfield, M.D. (1942-2020): Legacy in Leukemia Research.
PMID: 32463139 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 28, 2020 Category: Cancer & Oncology Authors: Grever MR Tags: Oncologist Source Type: research

A phase II trial of cabozantinib in hormone-receptor positive breast cancer with bone metastases.
CONCLUSION: Bone scans improved in 38% of patients with metastatic hormone receptor positive breast cancer and remained stable in an additional 12% for a minimum duration of 12 weeks on cabozantinib. Further investigations should assess the activity of cabozantinib in combination with other hormonal and other breast cancer therapies and determine whether bone scan responses correlate with meaningful antitumor effects. IMPLICATION FOR PRACTICE: Most patients with metastatic hormone receptor positive (HR+) breast cancer have bone involvement, and many have bone-only disease which is difficult to evaluate for resp...
Source: The Oncologist - May 28, 2020 Category: Cancer & Oncology Authors: Xu J, Higgins MJ, Tolaney SM, Come SE, Smith MR, Fornier M, Mahmood U, Baselga J, Yeap BY, Chabner BA, Isakoff SJ Tags: Oncologist Source Type: research

Patient-Reported Outcomes in Oncology Clinical Trials: Stakeholder Perspectives from the Accelerating Anticancer Agent Development and Validation Workshop 2019.
PMID: 32463153 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 28, 2020 Category: Cancer & Oncology Authors: Bhatnagar V, Hudgens S, Piault-Louis E, Jones L, Beaver JA, Lyerly HK, Reaman G, Fleming T, Kluetz PG Tags: Oncologist Source Type: research

Accrual, Publication Bias, and the Coronavirus in 2020.
PMID: 32462787 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 27, 2020 Category: Cancer & Oncology Authors: Bates SE Tags: Oncologist Source Type: research

A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting.
CONCLUSION: Ultralow-dose 0.005% estriol vaginal gel did not significantly influence estrogens, FSH, and LH levels in women with breast cancer receiving NSAI. A transient negligible absorption of estriol and a nonsignificant variation of FSH after 12 weeks were observed. These findings provide confidence for the safe use of 0.005% estriol vaginal gel in women with breast cancer with an indication for treatment with vaginal estrogens. PMID: 32459035 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 27, 2020 Category: Cancer & Oncology Authors: Sánchez-Rovira P, Hirschberg AL, Gil-Gil M, Bermejo-De Las Heras B, Nieto-Magro C Tags: Oncologist Source Type: research

A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma.
CONCLUSION: PBI-05204 did not meet its primary endpoint for OS in this study. Recent preclinical data indicate a role for PBI-05204 against glioblastoma multiforme when combined with chemotherapy and radiotherapy. A randomized phase II trial is currently being designed. PMID: 32452588 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 26, 2020 Category: Cancer & Oncology Authors: Roth MT, Cardin DB, Borazanci EH, Steinbach M, Picozzi VJ, Rosemury A, Wadlow RC, Newman RA, Berlin J Tags: Oncologist Source Type: research

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
In conclusion, the combination of continuous dosing of veliparib and every-3-week carboplatin demonstrated activity and an acceptable toxicity profile. Decrease in SUVmax on 18 FLT-PET scan during the first cycle of this therapy can identify patients who are likely to have a response. IMPLICATIONS FOR PRACTICE: The BROCADE studies suggest that patients with BRCA mutation benefit from addition of the poly(ADP-ribose) polymerase inhibitor veliparib to carboplatin plus paclitaxel. This study demonstrates that a higher dose of veliparib is tolerable and active in combination with carboplatin alone. With growing interest in ima...
Source: The Oncologist - May 26, 2020 Category: Cancer & Oncology Authors: Wesolowski R, Stover DG, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Carey A, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona Tags: Oncologist Source Type: research

Frequency, Timing and Predictors of Palliative Care Consultation in Patients with Advanced Cancer at a Tertiary Cancer Center: Secondary Analysis of Routinely Collected Health Data.
CONCLUSION: A minority of patients with advanced cancer received PC consultation at the tertiary cancer center, occurring late in the disease trajectory. Frequency and timing of PC consultation varied significantly, according to multiple factors. IMPLICATIONS FOR PRACTICE: Clinical and demographic factors are associated with variations in frequency and timing of palliative care consultation at a cancer center, and may in some cases reflect barriers to access that warrant attention. PMID: 32445194 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 22, 2020 Category: Cancer & Oncology Authors: Watanabe S, Faily V, Mawani A, Huot A, Tarumi Y, Potapov A, Fassbender K, Fairchild A, Joy AA, King KM, Roa W, Venner CP, Baracos VE Tags: Oncologist Source Type: research

Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China.
CONCLUSION: A simple CGA in older adults with DLBCL may be an effective tool for guiding therapeutic strategies in China. IMPLICATIONS FOR PRACTICE: Diffuse large B-cell lymphoma (DLBCL) is the most common malignant lymphoma in older adults. The simple tool, Comprehensive Geriatric Assessment (CGA), is proved to be an effective method to identify older adults with DLBCL who are suitable for standard-dose R-CHOP regimen therapy. This is the first prospective trial in China to evaluate the tolerability and efficacy of CGA-driven therapy for older adults with DLBCL, and the result showed that this simple CGA may be an ef...
Source: The Oncologist - May 20, 2020 Category: Cancer & Oncology Authors: Bai JF, Han HX, Feng R, Li JT, Wang T, Zhang CL, Liu H Tags: Oncologist Source Type: research

Are Cyclin-Dependent Kinase 4/6 Inhibitors Without Future in Neuroendocrine Tumors?
PMID: 32436279 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 20, 2020 Category: Cancer & Oncology Authors: Pusceddu S, Corti F, Milione M, Centonze G, Prinzi N, Torchio M, de Braud F Tags: Oncologist Source Type: research

Fluoropyrimidine-Associated Cardiotoxicity: Probably Not So Rare As It Seems.
PMID: 32436298 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 20, 2020 Category: Cancer & Oncology Authors: Lestuzzi C, Tratuferi L, Viel E, Buonadonna A, Vaccher E, Berretta M Tags: Oncologist Source Type: research

Fluoropyrimidine-Associated Cardiotoxicity: The Reply.
PMID: 32436313 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 20, 2020 Category: Cancer & Oncology Authors: Raber I, Peters ML, Asnani A Tags: Oncologist Source Type: research

In Reply.
PMID: 32436340 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 20, 2020 Category: Cancer & Oncology Authors: Grande E, Molina-Cerrillo J, Alonso-Gordona T Tags: Oncologist Source Type: research

Impact of delayed neoadjuvant systemic chemotherapy on overall survival among breast cancer patients.
CONCLUSIONS: A delay in NSC initiation of more than 61 days after BC diagnosis was associated with an increased risk of death. Early initiation of NSC should be a priority; multidisciplinary teams must focus in coordination of care and patient-centered timely treatment planning and delivery. IMPLICATIONS FOR PRACTICE: As we demonstrated that a delay in neoadjuvant systemic chemotherapy initiation of more than 61 days after breast cancer diagnosis is associated with an increased risk of death, efforts must focus on early initiation of therapy, which should be a priority; multidisciplinary teams must enhance coor...
Source: The Oncologist - May 20, 2020 Category: Cancer & Oncology Authors: Gagliato DM, Lei X, Giordano SH, Valero V, Barcenas CH, Hortobagyi GN, Chavez-MacGregor M Tags: Oncologist Source Type: research

A retrospective analysis of the safety and activity of Lutetium-177-PSMA radionuclide treatment in older patients with metastatic castration-resistant prostate cancer.
CONCLUSION: Our results indicate that Lu-PSMA is safe and active in elderly patients with mCRPC. IMPLICATION FOR PRACTICE: Lutetium-177-PSMA (Lu-PSMA), a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA), enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer (mCRPC). The recently published single-arm phase II trial with LU-PSMA, describing its safety and activity, did not include patients over 75. We retrospectively analyzed Lu-PSMA activity in patients over 75 and found that treatment was tolerable and similarly active in this age ...
Source: The Oncologist - May 19, 2020 Category: Cancer & Oncology Authors: Leibowitz R, Davidson T, Gadot M, Aharon M, Malki A, Levartovsky M, Oedegaard C, Saad A, Sandler I, Ben-Haim S, Domachevsky L, Berger R Tags: Oncologist Source Type: research

Navigating roadblocks as an early career attending … literally.
Navigating roadblocks as an early career attending… literally. Oncologist. 2020 May 18;: Authors: Olilla TA PMID: 32420663 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 18, 2020 Category: Cancer & Oncology Authors: Olilla TA Tags: Oncologist Source Type: research

Regarding: TELEPRO: patient reported carcinoid syndrome symptom improvement following initiation of Telotristat ethyl in the real world.
PMID: 32420675 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 18, 2020 Category: Cancer & Oncology Authors: Hota S, Srirajaskanthan R Tags: Oncologist Source Type: research

Oncologist's perspective: when cancer encounters COVID-19.
PMID: 32412653 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 15, 2020 Category: Cancer & Oncology Authors: Gao Z, Yang Y, Ding C, Niu P, Huang W, Lei F, Gu J Tags: Oncologist Source Type: research

Personalized risk-benefit ratio adaptation of Breast Cancer care at the epicentre of Covid-19 outbreak.
Abstract Northern Italy has been one of the European regions reporting the highest number of Covid-19 cases and deaths. The pandemic spread has challenged the National Health System (NHS), requiring re-allocation of most of the available healthcare resources to treat Covid-19 positive patients, generating a competition with other healthcare needs, including cancer. Cancer patients are at higher risk of developing critical illness after Covid-19 infection. Thus, mitigation strategies should be adopted to reduce the likelihood of infection in all cancer patients. At the same time, suboptimal care and treatments may ...
Source: The Oncologist - May 15, 2020 Category: Cancer & Oncology Authors: Viale G, Licata L, Sica L, Zambelli S, Zucchinelli P, Rognone A, Aldrighetti D, Di Micco R, Zuber V, Pasetti M, Di Muzio N, Rodighiero MG, Panizza P, Sassi I, Petrella G, Cascinu S, Gentilini OD, Bianchini G Tags: Oncologist Source Type: research

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer.
CONCLUSIONS: Regorafenib and nivolumab combination was associated with modest clinical activity in patients with MSS chemotherapy-resistant metastatic colorectal cancer. Selection for patients without history of liver metastases may identify a cohort of patients with MSS colorectal cancer with a higher likelihood of benefit from this combination. ctDNA may represent a powerful tool for predicting early therapeutic efficacy of immunotherapy in the MSS colorectal cancer population. IMPLICATIONS FOR PRACTICE: This study showed that the combination of regorafenib and nivolumab was associated with a modest clinical activit...
Source: The Oncologist - May 14, 2020 Category: Cancer & Oncology Authors: Wang C, Chevalier D, Saluja J, Sandhu J, Lau C, Fakih M Tags: Oncologist Source Type: research

Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
CONCLUSION: We developed an IHC-based approach to classify TNBCs into molecular subtypes. This IHC-based classification can provide additional information for prognostic evaluation. It allows for subgrouping of TNBC patients in large clinical trials and evaluating the efficacy of targeted therapies within certain subtypes. It has potential to be routinely used to guide treatment decisions for patients with TNBC. IMPLICATIONS FOR PRACTICE: We developed an immunohistochemistry (IHC)-based classification approach for triple-negative breast cancer (TNBC), which exhibited substantial agreement with the mRNA expression-base...
Source: The Oncologist - May 14, 2020 Category: Cancer & Oncology Authors: Zhao S, Ma D, Xiao Y, Li XM, Ma JL, Zhang H, Xu XL, Lv H, Jiang WH, Yang WT, Jiang YZ, Zhang QY, Shao ZM Tags: Oncologist Source Type: research

Statin Intolerance, anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?
We present a case of a patient with advanced non-small cell lung cancer who developed grade 4 myositis with concurrent myocarditis early after initiation of anti-programmed death ligand 1 therapy (durvalumab). Autoantibody analysis revealed marked increases in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody levels that preceded clinical toxicity, and further increased during toxicity. Notably, the patient had a history of intolerable statin myopathy, which had resolved clinically after statin discontinuation and prior to ICI initiation. This case demonstrates a potential association between statin exposure, a...
Source: The Oncologist - May 13, 2020 Category: Cancer & Oncology Authors: von Itzstein MS, Khan S, Popat V, Lu R, Khan SA, Fattah FJ, Park JY, Bermas BL, Karp DR, Ahmed M, Saltarski JM, Gloria-McCutchen Y, Xie Y, Li QZ, Wakeland EK, Gerber DE Tags: Oncologist Source Type: research

How to Manage Febrile Neutropenia During the COVID Pandemic?
PMID: 32399999 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 12, 2020 Category: Cancer & Oncology Authors: Boutayeb S, El Ghissassi I, Mrabti H, Errihani H Tags: Oncologist Source Type: research

A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.
CONCLUSION: Neither EDT nor mTOR inhibition improved outcomes in FLC. Other treatment strategies are needed. PMID: 32400000 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 12, 2020 Category: Cancer & Oncology Authors: El Dika I, Mayer RJ, Venook AP, Capanu M, LaQuaglia MP, Kobos R, O'Neill AF, Chou JF, Ly M, Ang C, O'Reilly EM, Gordan JD, Abou-Alfa GK Tags: Oncologist Source Type: research

Opioids for Breakthrough Cancer Pain.
Authors: PMID: 32400059 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 12, 2020 Category: Cancer & Oncology Tags: Oncologist Source Type: research

The Endless Question of Opioid Doses for Breakthrough Pain.
Authors: PMID: 32400063 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 12, 2020 Category: Cancer & Oncology Tags: Oncologist Source Type: research

Emerging Therapeutic Implications of STK11 Mutation: Case Series.
We present three patients with STK11-mutated tumors and discuss the proposed mechanisms by which germline and somatic alterations in STK11 promote carcinogenesis, potential approaches for therapeutic targeting, and the new data on resistance to immune checkpoint inhibitors. KEY POINTS: STK11 is a tumor suppressor gene, and loss-of-function mutations are oncogenic, due at least in part to loss of AMPK regulation of mTOR and HIF-1-α. Clinical trials are under way, offering hope to patients whose STK11-mutated tumors are refractory and/or have progressed on chemotherapeutic regimens. Whether gastrointestinal cancers wit...
Source: The Oncologist - May 12, 2020 Category: Cancer & Oncology Authors: Laderian B, Mundi P, Fojo T, Bates S Tags: Oncologist Source Type: research

Cancer Care for All? Tales of Caring for Undocumented Patients with Cancer.
PMID: 32396688 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 12, 2020 Category: Cancer & Oncology Authors: Olazagasti C, Duma N Tags: Oncologist Source Type: research

Prolonged Opioid Use After Surgery for Early-Stage Breast Cancer.
This study examined the patterns of prolonged opioid use and the factors associated with higher risk of prolonged opioid use among opioid-naïve working-age patients with early-stage breast cancer. METHODS: Using MarketScan data, the study identified 23,440 opioid-naïve patients who received surgery for breast cancer between January 2000 and December 2014 and filled at least one opioid prescription attributable to surgery. Prolonged opioid use was defined as one or more prescriptions for opioids within 90 to 180 days after surgery and defined extra-prolonged opioid use as one or more opioid prescriptio...
Source: The Oncologist - May 11, 2020 Category: Cancer & Oncology Authors: Shen C, Thornton JD, Gu D, Dodge D, Zhou S, He W, Zhao H, Giordano SH Tags: Oncologist Source Type: research

Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer.
CONCLUSION: The combination of moxifloxacin with previous TPC shows promising efficacy and well-tolerated toxicities in patients with MBC. PMID: 32390277 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 11, 2020 Category: Cancer & Oncology Authors: Wang X, Shi W, Li J, Huang Z, Xia W, Huang J, Su Y, Wang S, Shi Y, Bi X, Yuan Z Tags: Oncologist Source Type: research

Immune Checkpoint Inhibitors Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
CONCLUSION: Our study represents the largest clinical description and characterization of PAI-irAE. Although ICI-associated PAI is a rare adverse event, early recognition is important to implement corticosteroid treatment. Further studies are required to elucidate risk factors and reversibility of this rare but severe irAE. Clinical trial identification number. NCT03492242 IMPLICATIONS FOR PRACTICE: Immune checkpoint inhibitor (ICI)-associated primary adrenal insufficiency (PAI) is a rare adverse event that is important to recognize because it may be severe and life-threatening, requiring emergent and often lifelong hormon...
Source: The Oncologist - May 10, 2020 Category: Cancer & Oncology Authors: Grouthier V, Lebrun-Vignes B, Moey M, Johnson DB, Moslehi JJ, Salem JE, Bachelot A Tags: Oncologist Source Type: research

Cervical Cancer in Young Women: Do They Have a Worse Prognosis? A Retrospective Cohort Analysis in a Population of Mexico.
CONCLUSION: We corroborated that age at diagnosis is not a prognostic factor for decreased or increased OS or DFS, and in both groups, the stage, histologic subtype, hydronephrosis, and node involvement were identified as factors adverse to OS and DFS, and pregnancy history was a protective factor in DFS. IMPLICATIONS FOR PRACTICE: The present study directly affects everyday clinical practice because it allows us to focus on the most relevant prognostic factors in patients with cervical cancer. When planning treatment and follow-up, clinicians should focus on stage at diagnosis, histologic subtype, hydronephrosis, and...
Source: The Oncologist - May 10, 2020 Category: Cancer & Oncology Authors: Isla-Ortiz D, Palomares-Castillo E, Mille Loera JE, Ramírez-Calderón N, Mohar-Betancourt A, Meneses-García AA, Reynoso-Noverón N Tags: Oncologist Source Type: research

Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients.
CONCLUSION: A trend toward worse FFLR was seen in HIV-positive patients, despite similar baseline disease characteristics as HIV-negative patients. Worse FFLR and OS was significantly associated with increased time from diagnosis to treatment initiation. Poorer OS was seen in HIV-positive patients with a post-treatment CD4 count less than 150 cells per mm3 . IMPLICATIONS FOR PRACTICE: Human immunodeficiency virus (HIV)-positive patients with anal squamous cell carcinoma can represent a difficult clinical scenario. Definitive radiation with concurrent chemotherapy is highly effective, but can result in significant toxi...
Source: The Oncologist - May 10, 2020 Category: Cancer & Oncology Authors: Susko M, Wang CJ, Lazar AA, Kim S, Laffan A, Feng M, Ko A, Venook AP, Atreya CE, Van Loon K, Anwar M Tags: Oncologist Source Type: research

Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801.
CONCLUSION: Our data do not support maintenance GEM after biweekly CBDCA+GEM in elderly patients with NSCLC. PMID: 32385918 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 9, 2020 Category: Cancer & Oncology Authors: Takayama K, Takeshita M, Inoue K, Ichiki M, Fujita M, Harada T, Shiraishi Y, Wataya H, Tokunaga S, Yamada T, Uchino J, Sugio K Tags: Oncologist Source Type: research

Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.S.
Abstract Despite the Centers for Medicare and Medicaid Services' recent approval to increase payments for inpatient-delivered chimeric antigen receptor T-cell therapy (CAR-T) for adult lymphoma, reimbursement remains far below the costs of the product and overall treatment of the therapy. We surveyed 92 CAR-T-certified centers in the U.S. to assess the perceived financial viability and related challenges for treating adult patients with lymphoma. Of 92 certified CAR-T centers in the U.S., 20 (22%) directors or chief medical officers responded. More than three quarters of facilities reported treating patients in an...
Source: The Oncologist - May 9, 2020 Category: Cancer & Oncology Authors: Leech A, Neumann PJ, Cohen JT, Jagasia M, Dusetzina SB Tags: Oncologist Source Type: research

Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
CONCLUSION: Positive PD-L1 expression was associated with unfavorable clinical outcomes in patients with ALK-positive lung ADC receiving crizotinib. IMPLICATIONS FOR PRACTICE: Not all lung adenocarcinoma with sensitizing driver mutations experienced durable responses to small-molecule tyrosine kinase inhibitors (TKIs). Similar to the negative impact of programmed death-ligand 1 (PD-L1) in epidermal growth factor receptor mutant tumors treated with TKIs, this study demonstrated that positive PD-L1 expression was also associated with worse response rate and shorter progression-free survival of anaplastic lymphoma kinase...
Source: The Oncologist - May 9, 2020 Category: Cancer & Oncology Authors: Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Liu YN, Su KY, Chang YL, Wu CT, Liao BC, Hsu CC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ Tags: Oncologist Source Type: research

Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey.
CONCLUSION: Compared with the original FRONTLINE survey, FRONTLINE 2 reveals some differences in the management of VTE in patients with cancer. Newer anticoagulants such as fondaparinux, dabigatran, and rivaroxaban are being incorporated into the contemporary management of VTE in patients with cancer. IMPLICATIONS FOR PRACTICE: This globally conducted survey of more than 5,000 cancer clinicians revealed a number of insights into the perceived risk for venous thromboembolism as well as contemporary approaches to its prevention and treatment. Although guidelines have consistently recommended anticoagulant medications fo...
Source: The Oncologist - May 8, 2020 Category: Cancer & Oncology Authors: Kakkar AK, Bauersachs R, Falanga A, Wong J, Kayani G, Kahney A, Hughes R, Levine M Tags: Oncologist Source Type: research

Authors Reply: How to manage febrile neutropenia during the COVID pandemic? In response to, "A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic".
Authors Reply: How to manage febrile neutropenia during the COVID pandemic? In response to, "A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic". Oncologist. 2020 May 07;: Authors: Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C PMID: 32378772 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 7, 2020 Category: Cancer & Oncology Authors: Authors Reply: How to manage febrile neutropenia during the COVID pandemic? In response to, "A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic". Tags: Oncologist Source Type: research

Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16 α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications. Oncologist. 2020 May 06;: Authors: Kurland BF, Wiggins JR, Coche A, Fontan C, Bouvet Y, Webner P, Divgi C, Linden HM Abstract Estrogen receptor (ER) status by immunohistochemistry (IHC) of cancer tissue is currently used to direct endocrine therapy in breast cancer. Positron emission tomography (PET) with 16α-18F-fluoro-17β-estradiol (18 F-FES) noninvasively...
Source: The Oncologist - May 6, 2020 Category: Cancer & Oncology Authors: Kurland BF, Wiggins JR, Coche A, Fontan C, Bouvet Y, Webner P, Divgi C, Linden HM Tags: Oncologist Source Type: research

Delta-like Protein 3 Expression and Targeting in Merkel Cell Carcinoma.
CONCLUSIONS: DLL3 overexpression is very common in MCC by IHC. The response to treatment suggests that DLL3 expression may have predictive relevance for DLL3-targeting therapies in MCC. IMPLICATIONS FOR PRACTICE: Delta-like protein 3 (DLL3) is being developed as a predictive biomarker to identify patients for treatment with DLL3-targeting agents. Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. We found that DLL3 overexpression is very common in MCC by immunohistochemistry and significantly associated with Merkel cell polyomavirus expression. Despite the lack of prognostic significanc...
Source: The Oncologist - May 5, 2020 Category: Cancer & Oncology Authors: Xie H, Kaye FJ, Isse K, Sun Y, Ramoth J, French DM, Flotte TJ, Luo Y, Saunders LR, Mansfield AS Tags: Oncologist Source Type: research

Dual Fulvestrant-Trametinib Therapy in Recurrent Low-Grade Serous Ovarian Cancer.
PMID: 32369640 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 5, 2020 Category: Cancer & Oncology Authors: Bussies P, Schlumbrecht M Tags: Oncologist Source Type: research

Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform.
CONCLUSION: Based on our observations, it seems that PCM might be a feasible approach for advanced gynecologic cancers with limited treatment options. IMPLICATIONS FOR PRACTICE: Nowadays molecular profiling of advanced gynecologic malignancies is feasible in the clinical routine. A molecular portrait should be done for every patient with an advanced therapy-refractory gynecologic malignancy to offer molecular-based treatment concepts. PMID: 32369643 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 5, 2020 Category: Cancer & Oncology Authors: Taghizadeh H, Mader RM, Müllauer L, Aust S, Polterauer S, Kölbl H, Seebacher V, Grimm C, Reinthaller A, Prager GW Tags: Oncologist Source Type: research

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.
CONCLUSION: In a high proportion of patients with MSI-high cancers and poor performance status related to end-stage disease, salvage immunotherapy can induce potentially long-lasting "Lazarus responses." Immunotherapy decisions near the end-of-life should be carefully integrated with predictive biomarkers and with palliative care measures in the real-world setting. IMPLICATIONS FOR PRACTICE: In this retrospective cohort study of 27 pretreated patients with microsatellite instability (MSI)-high cancers and Eastern Cooperative Oncology Group performance status of 2 or 3 not related to comorbidities, PD-1/PD-L1...
Source: The Oncologist - May 5, 2020 Category: Cancer & Oncology Authors: Pietrantonio F, Loupakis F, Randon G, Raimondi A, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, Morano F, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassan M, Lonardi S, Curigliano G, Fucà G, Di B Tags: Oncologist Source Type: research

A Neuroendocrine Tumor Specialty Center in New Orleans (NOLANETS) Response to Patient Care During the COVID-19 Pandemic.
PMID: 32369669 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 5, 2020 Category: Cancer & Oncology Authors: Ramirez RA, Bren-Mattison Y, Thiagarajan R, Boudreaux JP, Marsala AJ, Ryan P, Maluccio MA Tags: Oncologist Source Type: research

Significant Benefits of Osimertinib against Adenosquamous Carcinoma Harboring Germline T790M Mutation.
CONCLUSION: Osimertinib can be a treatment option for patients with lung ASC harboring germline EGFR T790M mutation. PMID: 32367600 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 4, 2020 Category: Cancer & Oncology Authors: Huo R, Li J, Li X, Shi J, Wang K, Jiao J, Shang Y Tags: Oncologist Source Type: research

A Phase Ib Study of Single Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
PMID: 32356383 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - April 30, 2020 Category: Cancer & Oncology Authors: Borazanci E, Pishvaian MJ, Weekes C, Huang J, Rajakumaraswamy N Tags: Oncologist Source Type: research

I have cancer - now what?
PMID: 32353186 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - April 30, 2020 Category: Cancer & Oncology Authors: Christiansen NP Tags: Oncologist Source Type: research

HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer.
Abstract BACKGROUND: HER2 overexpression has been investigated as a potential biomarker and therapeutic target in biliary tract cancer (BTC), but a prognostic role of such alteration has not been demonstrated yet. MATERIALS AND METHODS: We retrospectively evaluated HER2 protein expression by immunohistochemistry (IHC) in 100 radically resected BTC patients. HER2 gene amplification was assessed by fluorescence in situ hybridization (FISH) in 2+ and 3+ cases at IHC. High HER2 protein expression was defined as either IHC 3+ or 2+ associated with FISH positivity. The primary objective of the study was to evaluate...
Source: The Oncologist - April 30, 2020 Category: Cancer & Oncology Authors: Vivaldi C, Fornaro L, Ugolini C, Niccoli C, Musettini G, Pecora I, Cacciato Insilla A, Salani F, Pasquini G, Catanese S, Lencioni M, Masi G, Campani D, Fontantini G, Falcone A, Vasile E Tags: Oncologist Source Type: research

Do I Know You?
PMID: 32353196 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - April 30, 2020 Category: Cancer & Oncology Authors: Murphy M Tags: Oncologist Source Type: research

Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study.
CONCLUSION: Apatinib was effective as second- or further-line treatment for advanced esophageal cancer. PMID: 32342599 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - April 27, 2020 Category: Cancer & Oncology Authors: Yanwei L, Feng H, Ren P, Yue J, Zhang W, Tang P, Shang X, Pang Q, Liu D, Chen C, Pan Z, Tao YZ Tags: Oncologist Source Type: research